Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis

Clin Appl Thromb Hemost. 2007 Oct;13(4):362-8. doi: 10.1177/1076029607305580.

Abstract

Sepsis-induced systemic inflammation results in coagulation abnormalities that may be different in gram-positive and gram-negative infections. We used ciprofloxacin to induce a predominantly gram-positive Enterococcus faecalis polymicrobial sepsis in rats. Ciprofloxacin-untreated rats exhibited a predominantly gram-negative polymicrobial sepsis. Rats were subjected to 30% body surface area burn (B), cecal ligation puncture (CLP) with a 22-gauge needle, and B + CLP. Ciprofloxacin-treated B + CLP rats showed a significant decrease in plasma thrombin activatable fibrinolysis inhibitor (TAFI) levels compared with sham rats. However, plasma tissue factor pathway inhibitor (TFPI) levels decreased significantly in B, CLP, and B + CLP groups compared with sham rats. The ciprofloxacin-untreated group showed a significant decrease in plasma TAFI levels in CLP and B + CLP and plasma TFPI levels decreased in all 3 groups compared with sham rats. Histological changes in the liver and kidney included vascular congestion and parenchyma bleed following B + CLP in ciprofloxacin-untreated rats. These results suggest that plasma TAFI and TFPI levels differ depending on the type of bacteria involved in the septic process.

MeSH terms

  • Animals
  • Carboxypeptidase B2 / blood*
  • Ciprofloxacin / administration & dosage
  • Enterococcus faecalis
  • Gram-Negative Bacterial Infections / blood
  • Gram-Positive Bacterial Infections / blood
  • Kidney / pathology
  • Lipoproteins / blood*
  • Liver / pathology
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Sepsis / blood*
  • Sepsis / microbiology
  • Sepsis / pathology

Substances

  • Lipoproteins
  • lipoprotein-associated coagulation inhibitor
  • Ciprofloxacin
  • Carboxypeptidase B2